Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals

被引:1
作者
Patil, Rucha [1 ]
Shanbhag, Sharda [1 ]
Shankarkumar, Aruna [1 ]
Madkaikar, Manisha [1 ]
机构
[1] ICMR Natl Inst Immunohaematol, Dept Haemostasis & Thrombosis, Mumbai, Maharashtra, India
关键词
BBV152; ChAdOx1; nCov-19; neutralizing antibody; SARS-CoV-2; infection; spike-specific antibody; vaccination;
D O I
10.4103/ijmr.ijmr_3330_21
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: During the COVID-19 pandemic it was important to assess the antibody profile in individuals vaccinated with Covaxin (BBV152) and Covishield (ChAdOx1 nCoV-19) with both 28 and 84 days gaps between two doses, those infected with SARS-CoV-2 and post-COVID-19-infected individuals vaccinated with only one dose of either of the vaccines. The present study was aimed to assess these objectives. Methods: Fifty real time reverse transcription-polymerase chain reaction (qRT-PCR)-confirmed COVID19-infected individuals, along with 90 COVID-19-naive (BBV152 and ChAdOx1 nCov-19)-vaccinated individuals, were included in the study. Individuals who received a single dose of either vaccine with a confirmed past diagnosis of SARS-CoV-2 infection (n=15) were also included. Blood samples were collected strictly between the 4th and 5th wk after development of symptoms for SARS-CoV-2 infected individuals and after the first/second vaccination dose. Antibody profile assessment was done using whole-virus, spike-receptor binding domain (RBD) and nucleocapsid-specific ELISA kits along with neutralizing antibody kit. Results: There was an overall 97.7 per cent seropositivity rate in vaccinated individuals, and a strong correlation (R-2=0.8, P<0.001) between neutralizing and spike-RBD antibodies. Among individuals who received two standard doses of ChAdOx1 nCoV-19 vaccine, the spike antibody levels developed were of higher titre with a longer prime boost interval than in those with shorter intervals (P<0.01). Individuals vaccinated with two doses as well as only one dose post-SARS-CoV-2 infection had high neutralizing and spike-specific antibodies. Interpretation & conclusions: High neutralizing and spike-specific antibodies were developed in individuals vaccinated only with one dose of either vaccine post-SARS-CoV-2 infection. With the main priority being vaccinating majority of the population in our country, single-dose administration to such individuals would be a sensible way to make the most of the limited supplies. Furthermore, neutralizing antibody levels observed in COVID-19-naive vaccinees imply the need for booster vaccination.
引用
收藏
页码:538 / 545
页数:8
相关论文
共 15 条
  • [1] Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021
    Abu Jabal, Kamal
    Ben-Amram, Hila
    Beiruti, Karine
    Batheesh, Yunis
    Sussan, Christian
    Zarka, Salman
    Edelstein, Michael
    [J]. EUROSURVEILLANCE, 2021, 26 (06)
  • [2] bharatbiotech, BHARAT BIOTECH ANNOU
  • [3] Bradley Todd, 2021, medRxiv, DOI 10.1101/2021.02.03.21251078
  • [4] Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]
  • [5] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
    Folegatti, Pedro M.
    Ewer, Katie J.
    Aley, Parvinder K.
    Angus, Brian
    Becker, Stephan
    Belij-Rammerstorfer, Sandra
    Bellamy, Duncan
    Bibi, Sagida
    Bittaye, Mustapha
    Clutterbuck, Elizabeth A.
    Dold, Christina
    Faust, Saul N.
    Finn, Adam
    Flaxman, Amy L.
    Hallis, Bassam
    Heath, Paul
    Jenkin, Daniel
    Lazarus, Rajeka
    Makinson, Rebecca
    Minassian, Angela M.
    Pollock, Katrina M.
    Ramasamy, Maheshi
    Robinson, Hannah
    Snape, Matthew
    Tarrant, Richard
    Voysey, Merryn
    Green, Catherine
    Douglas, Alexander D.
    Hill, Adrian V. S.
    Lambe, Teresa
    Gilbert, Sarah C.
    Pollard, Andrew J.
    [J]. LANCET, 2020, 396 (10249) : 467 - 478
  • [6] Convalescent plasma from people vaccinated after COVID-19 infection Comment
    Abu Jabal, Kamal
    Wiegler, Karine Beiruti
    Edelstein, Michael
    [J]. LANCET MICROBE, 2021, 2 (05): : E171 - E172
  • [7] Krammer F, 2021, ROBUST SPIKE ANTIBOD, DOI [DOI 10.1101/2021.01.29.21250653, 10.1101/2021.01.2921250653]
  • [8] Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
    Kumar, Nathella
    Padmapriyadarsini, C.
    Uma Devi, K.
    Banurekha, V
    Nancy, Arul
    Girish Kumar, C.
    Murhekar, Manoj
    Gupta, Nivedita
    Panda, Samiran
    Babu, Subash
    Bhargava, Balram
    [J]. INDIAN JOURNAL OF MEDICAL RESEARCH, 2021, 153 (05) : 671 - 676
  • [9] Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein
    Lei, Jian
    Kusov, Yuri
    Hilgenfeld, Rolf
    [J]. ANTIVIRAL RESEARCH, 2018, 149 : 58 - 74
  • [10] Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety
    Meng, Hanyan
    Mao, Jianhua
    Ye, Qing
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (06) : 2369 - 2375